Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia

Ruan, Li; Zhu, Jianguo; Pan, Cong; Hua, Xin; Yuan, Dongbo; Li, Zhengming; Zhong, Weide

doi:10.1155/2015/235895

Cited by 9 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of replication may be due in part to differences across studies in disease definition (varied use of IPSS scores, prostate volume, history of transurethral resection of the prostate, etc), participant recruitment from clinical trials, community cohorts, and hospital-based populations, or differences in age. Evaluation of associated variation reported in candidate gene analyses of BPH 28,30–32,34,37,38,88 and an evaluation of prostate volume 48 did not yield any suggestive results in the present study (Supplementary Table 3).…”

Section: Discussioncontrasting

confidence: 53%

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Hellwege

Stallings²,

Torstenson

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) results in a significant public health burden due to the morbidity caused by the disease and many of the available remedies. As much as 70% of men over 70 will develop BPH. Few studies have been conducted to discover the genetic determinants of BPH risk. Understanding the biological basis for this condition may provide necessary insight for development of novel pharmaceutical therapies or risk prediction. We have evaluated SNP-based heritability of BPH in two cohorts and conducted a genome-wide association study (GWAS) of BPH risk using 2,656 cases and 7,763 controls identified from the Electronic Medical Records and Genomics (eMERGE) network. SNP-based heritability estimates suggest that roughly 60% of the phenotypic variation in BPH is accounted for by genetic factors. We used logistic regression to model BPH risk as a function of principal components of ancestry, age, and imputed genotype data, with meta-analysis performed using METAL. The top result was on chromosome 22 in SYN3 at rs2710383 (p-value = 4.6 × 10 −7 ; Odds Ratio = 0.69, 95% confidence interval = 0.55–0.83). Other suggestive signals were near genes GLGC , UNCA13 , SORCS1 and between BTBD3 and SPTLC3 . We also evaluated genetically-predicted gene expression in prostate tissue. The most significant result was with increasing predicted expression of ETV4 (chr17; p-value = 0.0015). Overexpression of this gene has been associated with poor prognosis in prostate cancer. In conclusion, although there were no genome-wide significant variants identified for BPH susceptibility, we present evidence supporting the heritability of this phenotype, have identified suggestive signals, and evaluated the association between BPH and genetically-predicted gene expression in prostate.

show abstract

Section: Discussioncontrasting

confidence: 53%

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Hellwege

Stallings²,

Torstenson

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The sample size in each study ranged from 20 to 588. Total 23 case–control studies, 11 for CYP17 [ 2 , 5 , 16 , 27 – 34 ], 10 for VDR [ 15 – 17 , 34 – 40 ], and 4 studies for ACE I/D [ 41 – 44 ] polymorphisms were included in our meta-analysis (Table 1 ). Studies were carried out in two major ethnic populations; 13 studies were in Asian while 10 studies were in the Caucasian population.…”

Section: Resultsmentioning

confidence: 99%

“… [ 16 ] Lebanon Caucasian 68 79 VDR Taq-I,Bsm-I, Apa-I, Fok-I PCR-RFLP 65.98 ± 9.97 58.33 ± 10.14 YES Mixed 7 3. [ 17 ] China Asian 200 200 VDR Fok-I PCR-RFLP 73.9 ± 2.7 73.56 ± 2.68 YES HB 5 4. [ 34 ] China Asia 452 501 VDR Apa-I, Fok-I PCR-RFLP 58.02 ± 7.38 57.28 ± 7.61 YES HB 7 5.…”

Section: Resultsmentioning

confidence: 99%

Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia

Lin

Li²,

Liu

et al. 2022

Syst Rev

View full text Add to dashboard Cite

Background Benign prostate hyperplasia (BPH) is the most common urological problem in elderly males. Recent studies have reported polymorphism in various metabolic genes in BPH. However, their association with the susceptibility of BPH is still inconsistent. Here, we systematically reviewed and performed a meta-analysis of CYP17, VDR, and ACE genes to determine their precise association with the risk of BPH. Methods A comprehensive literature search for published studies on candidate gene associations involving vitamin D receptor (VDR), angiotensin-converting enzyme (ACE), and CYP17 genes with the risk of BPH was done up to April 2020 in PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar databases. Fixed/random effects models were used to estimate the odd’s ratio (OR) and 95% confidence intervals (CIs). Begg’s funnel plot was used to assess the potential for publication bias. Results We found a total of 23 studies containing 3461 cases and 3833 controls for these gene polymorphisms. A significant association of ACE gene polymorphism was observed under the recessive (II vs. ID + DD) model for BPH susceptibility compared to control subjects (overall OR = 1.67, 95% CI = 1.03–2.73). Similar trends were observed for ACE gene polymorphism in Caucasian (OR = 6.18, 95% CI = 1.38–27.68) and Asian (OR = 1.42, 95% CI = 0.99–2.03) populations under study. No significant association was observed in VDR and CYP17 gene polymorphisms in any dominant or recessive models. Conclusion Significant OR demonstrated the implication of ACE gene polymorphism in the proliferation of prostate tissue, which in turn is associated with BPH susceptibility. However, prospective studies at large scale and sample size are needed to confirm the current findings.

show abstract

“…Thus, it is known that the plasma level of 25(OH)D3 inversely dependent on the volume of the prostate gland (Haghsheno et al 2013). It has been shown that the polymorphism of the vitamin D receptor gene correlates with the frequency of prostate hyperplasia complicated by histological prostatitis and prostate cancer (Kivineva et al 1998;Gsur et al 2002;Ruan et al 2015;Xiao et al 2020). One of the multivariate analyses showed that the levels of 25(OH)D3, serum calcium adjusted for albumin, sex hormone binding globulin (SHBG), and high-density lipoprotein (HDL) significantly and inversely correlate with the prostate volume, which makes it possible to consider vitamin D as a natural prostatic antiproliferant (Haghsheno et al 2013;Zhang et al 2016).…”

Section: Vitamin D and Prostate Diseasesmentioning

confidence: 99%

Nutritional supplementation of the pharmacotherapy of prostate diseases

Братчиков¹,

Tyuzikov²,

Dubonos³

2021

RRP

View full text Add to dashboard Cite

Introduction: Nutritional supplementation is an integral part of modern pharmacotherapeutic strategies for prostate diseases with different levels of evidence for specific nutrients. Provitamin A (beta-carotene), vitamin A (retinol) and prostate diseases. Their effects have not been sufficiently studied, and the available data are conflicting to recommend them as a nutritional supplement. Vitamin E (tocopherol) and prostate diseases. Its effects have not been sufficiently studied, and the available data are conflicting to recommend it as a nutritional supplement. Vitamin C (ascorbic acid) and prostate diseases. Its effects have not been sufficiently studied, and the available data are conflicted to recommend it as a nutritional supplement. Vitamin K and prostate diseases. Its effects have not been sufficiently studied, and the available data are conflicted to recommend it as a nutritional supplement. Vitamin D and prostate diseases. The evidence base of the vitamin D prostatotropic effects has been accumulated, which allows us to consider its deficiency replacement as an effective nutritional supplement in prostate diseases. Omega-3 PUFAs and prostate diseases. They have universal physiological effects; however, the evidence base for their recommendation as a nutritional supplement for prostate diseases is still insufficient. Zinc and prostate diseases. Positive effects of zinc on the prostate gland are known for a fact and allow us to recommend it as a nutritional supplement for prostate diseases. Selenium and prostate diseases. The reliably proven positive effects of selenium on the prostate gland allow us to recommend it as a nutritional supplement for prostate diseases. Magnesium and prostate diseases. Its effects have not been sufficiently studied, and the available data are conflicting to recommend it as a nutritional supplement.

show abstract

Association between Single Nucleotide Polymorphism of Vitamin D Receptor Gene FokI Polymorphism and Clinical Progress of Benign Prostatic Hyperplasia

Cited by 9 publications

References 16 publications

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Systematic review and meta-analysis of candidate gene association studies of benign prostate hyperplasia

Nutritional supplementation of the pharmacotherapy of prostate diseases

Contact Info

Product

Resources

About